Trial Profile
RAA, a Selective Retinoic Acid Receptor Alpha Agonist as a predictor of response to SY-1425 in patients with Acute Myeloid Leukemia (AML) compared to Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2016
Price :
$35
*
At a glance
- Drugs Tamibarotene (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 07 Sep 2016 New trial record